# Crizotinib (XALKORI) for Hematologic Indications
# Criteria for Use
# August 2024

**VA Pharmacy Benefits Management Services and National Formulary Committee**

*The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.*

The Product Information should be consulted for detailed prescribing information.

See the VA National Formulary Committee Monograph on this drug at the *PBM INTRAnet* site for further information.

## Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive crizotinib.

- ☐ History of interstitial fibrosis or interstitial lung disease
- ☐ History of congenital long QT syndrome
- ☐ Unmanageable drug-drug interactions
- ☐ Inadequate bone marrow function (Absolute Neutrophil Count < 1000/mm$^3$, platelets < 50,000/mm$^3$, hemoglobin < 8g/dL), unless due to marrow involvement
- ☐ Pregnancy
- ☐ Lactating

## Inclusion Criteria

All of the following criteria must be met.

- ☐ Care is provided by a VA/VA Community Care hematology or oncology provider.
- ☐ Goals of care and role of Palliative Care consult have been discussed and documented.
- ☐ Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

### Additional Inclusion Criteria

The answer to ONE of the following criteria must be met:

- ☐ Patient with relapsed or refractory systemic Anaplastic Lymphoma Kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)
- ☐ Patient with unresectable, recurrent or refractory ALK-positive inflammatory myofibroblastic tumor (IMT)

### Additional Inclusion Criteria

- ☐ For patients who can become pregnant: Pregnancy must be excluded prior to receiving crizotinib.
- ☐ For patients who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for 45 days after stopping treatment.
- ☐ For patients with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for 90 days after stopping treatment.

## Other Justification

- ☐ _____

Prepared: August 2024. Contact: Berni Heron, Pharm.D., BCOP, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services (12PBM)